Objective: To investigate the efficacy of anti-herpetic virus nucleoside drugs in the treatment of adult infectious mononucleosis. Methods: The clinical data of 219 adult patients with infectious mononucleosis were analyzed retrospectively. 23 observation indicators of 5 major items were collected, including general information of patients, clinical symptoms and laboratory tests before treatment, symptom outcomes, and laboratory test outcomes. The patients were divided into antiviral treatment group and control group according to whether anti-herpetic virus nucleosides were used. The differences of observation indexes between the two groups were compared. Then, 1:1 propensity matching analysis was conducted by using 14 indicators from three major items,i.e.,general information, clinical symptoms before treatment, and laboratory tests before treatment as matching variables to compare the differences in symptom outcomes and laboratory test outcomes between the two groups. Results: Before propensity score matching there were significant differences in age, fever grade, lymphadenopathy, heterotypic lymphocyte ratio, liver function and serum EBV-DNA level between the two groups. Propensity score matching showed that there were 68 cases in antiviral treatment group and 68 cases in the control group. There was no statistical difference between the two groups in each observation index before treatment. After antiviral treatment, the time of fever regression and lymph node regression in the control group was better than that in the antiviral treatment group, and the results were statistically different. Conclusion: Compared with the control group, the antiviral group does not exhibit more advantages in terms of clinical symptom response time and laboratory indicator response time. |
[1] CAI X Y,EBELL M H,HAINES L. Accuracy of signs,symptoms,and hematologic parameters for the diagnosis of infectious mononucleosis:a systematic review and Meta-analysis[J].J Am Board Fam Med,2021,34(6):1141-1156.
[2] 杭敏,崔红,刘霞,等.传染性单核细胞增多症合并血性胸水1例[J].实用医学杂志,2012,26(1):1006-5725.
[3] 栾刚领,黎辉姗,王小琳,等.以眼睑水肿为首发症状的儿童传染性单核细胞增多症2例[J].实用医学杂志,2011,27(12):2302.
[4] SHI J J,CHU C,YU M,et al.Clinical warning of hemophagocytic syndrome caused by Epstein-Barr virus[J].Ital J Pediatr,2021,47(1):3.
[5] FUJIWARA S,NAKAMURA H.Chronic active Epstein-Barr virus infection:is it immunodeficiency,malignancy,or both?[J].Cancers(Basel),2020,12:3202.
[6] KURI A,JACOBS B M,VICKARYOUS N,et al.Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom[J].BMC Public Health,2020,20(1):912.
[7] HU H L,DENG H L,BI J,et al.Clinical characteristics and effectiveness of antiviral agents in hospitalized children with infectious mononucleosis in China:a multicenter retrospective study[J].Pediatr Investig,2021,5(3):188-194.
[8] WOMACK J,JIMENEZ M.Common questions about infectious mononucleosis[J].Am Fam Physician,2015,91(6):372-376.
[9] TORRE D,TAMBINI R.Acyclovir for treatment of infectious mononucleosis:a Meta-analysis[J].Scand J Infect Dis,1999,31(6):543-547.
[10] DEPAOR M,O'BRIEN K,FAHEY T,et al.Antiviral agents for infectious mononucleosis(glandular fever)[J].Cochrane Database Syst Rev,2016,12:CD011487.
[11] 李中跃.EB病毒相关传染性单核细胞增多症的诊治及常见并发症[J].中国小儿急救医学,2010,17(2):97-99.
[12] 高荣理,陈垂婉,蔡翠珠,等.EBV合并CMV感染的传染性单核细胞增多症患者T细胞免疫状态及炎症指标变化[J].中华医院感染学,2020,30(19):2975-2978.
[13] 戴莎莎,周凯.重组人干扰素α1b辅助治疗传染性单核细胞增多症疗效的前瞻性随机对照研究[J].中国当代儿科杂志,2020,22(9):953-957.
[14] RUYMBEKE H,SCHOUTEN J,SERMON F.EBV:not your Everyday Benign virus[J].Acta Gastroenterol Belg,2020,83(3):485-487.
[15] 祁正红,陈雪夏,林先耀,等.传染性单核细胞增多症患儿外周血淋巴细胞亚群、细胞因子、TLRs的表达变化及其临床意义[J].中国现代医学杂志,2020,30(12):51-56.
[16] 魏文秀,荆兰兰,刘新永,等.抗疱疹病毒药物化学研究新进展[J].药学学报,2020,55(4):575-584. |